<DOC>
	<DOCNO>NCT02256033</DOCNO>
	<brief_summary>The purpose study test whether mild liver impairment affect blood level istradefylline human . Decreased liver function could possibly increase istradefylline level .</brief_summary>
	<brief_title>Effect Mild Hepatic Impairment Pharmacokinetics Istradefylline</brief_title>
	<detailed_description>This multicenter , open-label , parallel group , single-dose study determine single-dose PK istradefylline subject mild hepatic impairment ( HI ) ( Child-Pugh Class A ) subject normal hepatic function . Ten subject mild HI ( Child-Pugh Class A ) 10 subject normal hepatic function ( match age , gender , race , BMI ) enrol . Enrollment subject normal hepatic function subsequent HI subject .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Istradefylline</mesh_term>
	<criteria>All subject : Nonsmoking male females 1875 year age , inclusive ; Men woman procreative potential must practice medically reliable double barrier method birth control ; Body mass index ( BMI ) : 18.035.0 kg/m2 , inclusive : Must abstain drug nutrient know moderate potent inhibitors/inducers CYP3A4 CYP1A enzymes . These agent discontinue least 4 week istradefylline dose ( Day 1 ) Followup visit . Negative result Screening Baseline follow screen laboratory test : urine drug screen ( amphetamine , barbiturate , benzodiazepine , opiate , cannabinoids , cocaine ) . Documented prescription use subject mild HI medication include urine drug abuse test permit long dose stable least 2 week ; Subjects Normal Hepatic Function Medical history without clinically significant ongoing pathology , opinion Investigator preclude subject 's participation , influence outcome study ; Subjects Mild Hepatic Impairment Stable , mild liver disease ( ChildPugh A [ 5 6 point ] ) ; cryptogenic , posthepatic , hepatitis B/C virus , alcoholic origin ; Stable hepatic impairment , define clinically significant change disease status within last 30 day , document subject 's recent medical history ; Additional inclusion criterion apply Female subject take oral contraceptive longterm injectable implantable hormonal contraceptive , pregnant , lactating , breastfeeding ; Known history treatment drug alcohol addiction within previous 12 month &gt; 14 untis alcohol consumption per week , alcohol consumption within 1 week prior dose ; Positive test result human immunodeficiency virus ( HIV ) , Hepatitis B surface antigen ; Difficulty fast eat standard meal provide ; Use tobacco nicotinecontaining product within 90 day study start Followup visit ( confirm urine cotinine test ) ; Subjects Hepatic Impairment Severe ascites Screening ; History current severe hepatic encephalopathy ( Grade 3 high ) Any follow laboratory parameter screen : 1 . Serum ALT &gt; 5 × upper limit normal range ( ULN ) ; 2 . Serum albumin &lt; 2.4 g/dL ; 3 . Platelet count &lt; 80,000/mm3 ; 4 . Hemoglobin &lt; 11 g/dL ; 5 . Absolute neutrophil count ( ANC ) &lt; 1.5 × 109/L ( &lt; 1.5 × 103/μL ) ; Biliary liver cirrhosis cause HI relate parenchymal disorder and/or disease liver , include hepatocellular carcinoma . Additional exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Mild hepatic impairment</keyword>
	<keyword>Healthy volunteer</keyword>
	<keyword>Istradefylline</keyword>
</DOC>